European Next Generation Sequencing Market
 

Like this? Share it with your network

Share

European Next Generation Sequencing Market

on

  • 3,761 views

An analyst briefing presentation by Frost & Sullivan life sciences research analyst Divyaa Ravishankar.

An analyst briefing presentation by Frost & Sullivan life sciences research analyst Divyaa Ravishankar.

Statistics

Views

Total Views
3,761
Views on SlideShare
3,761
Embed Views
0

Actions

Likes
3
Downloads
62
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

European Next Generation Sequencing Market Presentation Transcript

  • 1. European Next Generation Sequencing Market Present to the Future! Divyaa Ravishankar, Research Analyst Healthcare
  • 2. Divyaa Ravishankar Functional Expertise 3 years of life sciences expertise which mainly constitutes lab research and market research. Working with new technologies incorporated in lab research. Identifying emerging technologies and tracking technological and market developments across the life sciences domain. Place photo here Market sizing and revenue forecasting.Shadow Background Industry Expertise Lab research experience in the areas such as: for effect - Diagnostic Testing by Immuno-Chromatographic Techniques. - Genetic research in HLA typing. Experience base covering broad range of sectors, leveraging long-standing working relationships with leading industry participants globally in areas like: - Drug Discovery - Clinical Diagnostics - Pharmaceuticals and Biotechnology - Donor RegistriesDivyaa RavishankarResearch Analyst, What I bring to the TeamLife Sciences, • Sound technical understanding of the global markets for emerging technologies in the health sciences sector. • Ability to formulate action plans with strong communication and exceptional interpersonal skills leveraged forHealthcare - Europe development of business relationships.Frost & Sullivan Career Highlights • Currently working as a research analyst in the healthcare market research team at Frost & Sullivan.Chennai, India • Two years work experience as a Senior Genetic Research Analyst at Histogenetics Pvt. Ltd, Chennai which includes one year onsite wet lab training in Newyork, USA. • Represented Histogenetics Ltd. at the 22nd and 23rd European Immunogenetics and Histocompatibility Conferences held at Toulouse, France (2008) and Ulm, Germany (2009). • Represented Histogenetics Ltd. at the 35th American Society for Histocompatibility and Immunogenetics Conference at San Francisco, California, USA (2009). • Represented Histogenetics Ltd at the National Marrow Donor Programme (NMDP) at Minneapolis, USA (2009). • Has been part of a start up Indian stem cell donor registry DATRI Pvt. Ltd. Education • Master of Science (Hons.) in Biological Sciences from Birla Institute of Technology and Science, Pilani, India. 2
  • 3. Focus Points Next Generation Sequencing – A Technology Road Map Market Overview Industry Challenges Market Drivers and Restraints Market Forecasts Geographical Trends End-User Analysis Strategic Recommendations 3
  • 4. A Technology Road MapInsert chart and/or graph here Single-molecule Massively Real-time Parallel Sequencing Sequencing Capillary Sequencing Short-read Sequencers Microwell Pyrosequencing Second-generation SequencingGel-based Systems Sanger’s Sequencing 1990 2000 2005 2010 2011 4
  • 5. Market Overview and Segmentation European NGS Market Research Centres Service Providers Laboratories using NGS platforms as a research Laboratories providing sequencing tool for various findings. services commercially Major platform provider in Europe is Illumina Inc, with Life Technologies Corporation and Roche contributing significantly. Pacific Biosciences will contribute a small share in the first quarter of 2011. The European NGS market is expected to reach revenues of $1,042.2 million in 2017, at a compound annual growth rate (CAGR) of 20.8 per cent for the period 2010-2017. 5
  • 6. Industry Challenges Interpretation of Complex Data from Next-generation sequencing Platforms. Reduction in the Cost to Sequence Human Genomes. Industry Challenges Increased Breadth of Application Leading to Designing of Sequencers for Longer Reads. 6
  • 7. Market Drivers and Restraints Substitution of Microarray Europe is a Hub for Cost Advantages over Technology by NGS in a Research Laboratories the Sanger’s sequencing Number of Applications and Academicians, and Second-generation within the Research Promoting the Use of Sequencing Platforms Community NGS Drivers Drivers Restraints Restraints Multiplexing Capabilities in Accuracy and Standardisation Research Labs in Array Format have made are to be Achieved if NGS has Europe are Highly DNA Arrays a Popular Choice to be Applied in Diagnostic Dependant on Grants for Price-sensitive Testing Researchers 7
  • 8. Market Forecasts Note: All figures are rounded; the base year is 2010. Source: Frost & Sullivan 8
  • 9. Geographical Trends Illumina GA IIx and Hi Seq2000 are short-read sequencers. The firm also plans to Source: Frost & Sullivan introduce upgrades for both its HiSeq 2000 and HiSeq 1000 platforms in the spring and expects reagent costs to drop to around $5,000 per genome. Roche 454 GS FLX titanium series account for 22.18 per cent users in Europe. SoliD 3 Plus and SoliD 4 with its subsequent upgrade to 4hq account for 12.7 per cent of users. SoliD 5500xl and 5500 SoliD sequencers recently launched, will witness increasing adoption in many labs in 2011. Heliscope performs single molecule sequencing. Polonator stationed at the Max Planck Institute, Europe, works on the sequencing ligation protocol. PacBioRS - SMRT is on the verge of its release and will contribute to market share by the first quarter of 2011.Current next generation platforms in use, include the Hi Seq2000, Illumina GenomeAnalyzer IIx, SoliD 3 Plus, SoliD 4hq ,454 GS FLX Ti, Heliscope and Polonator. Geographical Distribution of Next Generation The United Kingdom Highest Sequencers in Europe Germany France 140 Spain 120 100 The Neatherlands 80 Increasing Italy 60 Belgium 40 20 Sweden 0 Switzerland m rm d er n Ne w y Fin ark ite Ic tria No any Au ce l Sw elg d itz ium Po nds Fr in Ki nd Sp y ga e S rwa Ge rlan th ede B an l do Ita a an rtu d ela nm s la l ng e Norway De Countries Un Austria Th e Th Finland Denmark Number of units installed Iceland Source: Frost & Sullivan Lowest Portugal 9
  • 10. End - User Analysis 10
  • 11. Important Factors when Choosing Next-Generation SequencingPlatforms Low Low High High Read length Data accuracy 1 2 3 4 5 1 2 3 4 5 Sequencing Low Breadth of Low throughput High High application 1 2 3 4 5 1 2 3 4 5 Low High Low High Instrument cost Sample volume 1 2 3 4 5 1 2 3 4 5 Cost of Low High Library Low High bioinformatics 1 2 3 4 5 construction 1 2 3 4 5 tools Low High Legal/regulatory Reagent cost constraints Low High 1 2 3 4 5 1 2 3 4 5Note: Above are the key factors influencing the choice of NGS platforms. The factors were rated on a scale of 1 to 5 with 1 = Low importanceand 5 = High importance based on the end user’s input. 11
  • 12. Score Chart A survey was conducted across 50 European labs. The participants were from companies providing sequencing services and research institutes. The platforms were rated on a scale of 1 to 5, with 1= Poor and 5 = Excellent, based on their performance and efficiency. Rank Instrument Score • Read length • Cost of data management / bioinformatic 1 HiSeq 2000 3.47 tools • Ease of sample preparation 2 Illumina GA IIx 3.45 • Data accuracy • Breadth of application 3 SoliD 3 Plus 3.18 • Throughput • Reagent cost 4 454 GS FLX Ti 2.7 5 SoliD 4 hq 2.44 Rank Instrument Score • High Throughput Genotyping 1 HiSeq 2000 3.3 • De novo sequencing • Whole genome re-sequencing • Diagnostics 2 Illumina GA IIx 2.9 • Chip sequencing • Metagenomics 3 Solid 3 Plus 2.8 • Targeted re-sequencing • m RNA profiling • Epigenetics 4 454 GS FLX Ti 2.3 5 Solid 4 hq 2.1 12
  • 13. Recommendations Addressing the needs of the research community. Clinical Results backed up by sound empirical evidence. Need for longer read lengths, greater coverage, increased breadth of A multidisciplinary approach. application, data accuracy. 13
  • 14. Next Steps Request a proposal for Growth Partnership Services or Growth Consulting Services to support you and your team to accelerate the growth of your company. (enquiries@frost.com) Join us at our annual Growth, Innovation, and Leadership 2011: A Frost & Sullivan Global Congress on Corporate Growth (www.gil- global.com) Register for Frost & Sullivan’s Growth Opportunity Newsletter and keep abreast of innovative growth opportunities (www.frost.com/news) 14
  • 15. Your Feedback Is Important to Us What would you like to see from Frost & Sullivan?Growth Forecasts?Competitive Structure?Emerging Trends?Strategic Recommendations?Other? Please inform us by rating this analyst briefing and provide us with any feedback you may have. 15
  • 16. Follow Frost & Sullivan on Facebook, LinkedIn,SlideShare, and Twitter http://www.facebook.com/FrostandSullivan http://www.linkedin.com/companies/4506 http://www.slideshare.net/FrostandSullivan http://twitter.com/frost_sullivan 16
  • 17. For Additional InformationKatja Feick Noel AndersonCorporate Communications European Vice PresidentHealthcare New Business Development0049 (0) 69 7703343 +44 (0)207 343 8389katja.feick@frost.com noel.anderson@frost.comSiddharth Saha Divyaa RavishankarDirector of Research Research AnalystHealthcare Healthcare+ 44 (0) 207 343 8374 +91-44-42044706siddharth.saha@frost.com divyaar@frost.com 17